Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Home
/
Trials
/
NCT00115219
NCT00115219
View on ClinicalTrials.gov
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
PHASE4
Completed
INTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
May 31, 2005
Conditions
Rheumatoid Arthritis
Interventions
DRUG
Etanercept
Sponsors
Lead Sponsor
Amgen
All Listed Sponsors
lead
Amgen
INDUSTRY